Conference Documentation: ADMET

Conference Documentation: ADMET

SMi is proud to announce the return of the 11th annual ADMET conference 2016 in London!

ADME and toxicology testing are one of the most important research activities related to new drug discovery. Ensuring a good ADMET study will accelerate approval and therefore commercialization of your drug product – and hence pharmacokinetics remain at the forefront of drug formulation and development
Since the pharmaceutical and biotechnology companies are utilising innovative technologies, ADME and toxicology screening at early stages of drug discovery and development process has become even more imperative.

Join us at SMi's 11th annual ADMET taking place on the 13th - 14th June 2016 in London. This event will explore novel and emerging
non- clinical ADME approaches, structure based prediction of ADME properties, PK/PD modeling to validate drug targets and toxicity and many more.


Day 1
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks
Nick Plant, Reader in Molecular Toxicology, University Of Surrey
9:10
Better models for understanding, predicting and avoiding drug induced liver injury
Ian Wilson, Chair, Drug Metabolism and Molecular Toxicology, Imperial College
9:50
Cell-based Models for Drug Transport, Metabolism Studies and Services
Na Li, Senior Staff Scientist, Corning, Inc
10:30
Morning Coffee
11:00
Humanized animal models – potential tools for the study of drug transporters
Laurent Salphati, Senior Scientist, Drug Metabolism and Pharmacokinetics, Genentech
11:40
In silico approaches to evidence-based mechanistic modelling
John Dearden, Emeritus Professor, Liverpool John Moores University
12:20
Networking Lunch
13:30
Application of PBPK to Drug Development in Rare Diseases
Pau Aceves, Senior Clinical Pharmacologist, Takeda UK Ltd
14:10
Early dose predictions - A valuable tool in risk assessment and optimization of small molecules
Carl Petersson, DMPK NCE Senior Designer, Merck Serono
14:50
Afternoon Tea
15:20
Integrated modelling of metabolism and PBPK
Nick Plant, Reader in Molecular Toxicology, University Of Surrey
16:00
Cross-platform/Cross-species Application of Physiologically Based Pharmacokinetics for Biologics
Armin Sepp, Manager, GSK
16:40
Human dose predictions from in vitro data: Validation using clinical data
Ken Page, Principal Scientist, RedX Immunology Ltd
17:20
Chairman’s Closing Remarks and Close of Day One
Day 2
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks
Nick Plant, Reader in Molecular Toxicology, University Of Surrey
9:50
Computational drug hazard assessment: From ADMET prediction towards organ toxicity
Friedemann Schmidt, Senior Scientist, Preclinical Safety, Sanofi-Aventis
9:50
Continuing challenges of performing accurate human dose predictions
Peter Littlewood, Director DMPK, Vertex Pharmaceuticals
10:30
Morning Coffee
11:00
Strategy to manage the risks associated with active transport of new chemical entities throughout the drug discovery and development process
Karelle Menochet, Principal Scientist, UCB
11:40
Translational modeling in support to efficacy and safety assessments
Thierry Lave, Head DMPK and TOX Project Leaders and Modeling & Simulation, Roche Pharmaceuticals
12:20
Networking Lunch
13:30
In Silico Predictions of Drug – Drug Interactions: Limitations and Perspectives
Mire Zloh, Head of Pharmaceutical Chemistry , University of Hertfordshire
14:10
Contribution of metabolites to DDI
Lena Gustavsson, Head of Section Drug-Drug Interactions , Lundbeck Limited
14:50
Afternoon Tea
15:20
Estimating human plasma concentrations using in silico
Mark Wenlock, Director, Insilicolynx
16:00
Role of drug transporters in drug delivery to CNS diseases
Kunal Taskar, Investigator, MET DMPK, RD Platform Technology , GSK
16:40
Chairman’s Closing Remarks and Close of Day Two

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook